Clinical outcome of AML patients with low vs high CRT levels
| . | All patients (n = 113) . | CRT < 200 ng/mL (n = 68) . | CRT > 200 ng/mL (n = 45) . | P . |
|---|---|---|---|---|
| CR1 achieved, % (n) | 70.8 (80) | 73.5 (50) | 66.6 (30) | |
| Death in CR1, % (n) | 2 | 2 | 0 | |
| Relapse of patients with CR1, % (n) | 47.6 (38/80) | 31.3 (25/80) | 16.3 (13/80) | |
| Refractory/non responder, % (n) | 29.2 (33/113) | 26.5 (18/68) | 33.3 (15/45) | |
| OS in months | 13.1 | 10.3 | 16.1 | .1160 |
| DFS in months | 9.1 | 7.5 | 11.2 | .0363 |
| Allogeneic transplantation, % (n) | 19.5 (22) | 50 (11) | 50 (11) | .2906 |
| Autologous transplantation, % (n) | 28.3 (32) | 62.5 (20) | 37.5 (12) | .0057 |
| No transplantation (incl. only chemotherapy), % (n) | 51.3 (59) | 62.1 (37) | 37.9 (22) | .1134 |
| . | All patients (n = 113) . | CRT < 200 ng/mL (n = 68) . | CRT > 200 ng/mL (n = 45) . | P . |
|---|---|---|---|---|
| CR1 achieved, % (n) | 70.8 (80) | 73.5 (50) | 66.6 (30) | |
| Death in CR1, % (n) | 2 | 2 | 0 | |
| Relapse of patients with CR1, % (n) | 47.6 (38/80) | 31.3 (25/80) | 16.3 (13/80) | |
| Refractory/non responder, % (n) | 29.2 (33/113) | 26.5 (18/68) | 33.3 (15/45) | |
| OS in months | 13.1 | 10.3 | 16.1 | .1160 |
| DFS in months | 9.1 | 7.5 | 11.2 | .0363 |
| Allogeneic transplantation, % (n) | 19.5 (22) | 50 (11) | 50 (11) | .2906 |
| Autologous transplantation, % (n) | 28.3 (32) | 62.5 (20) | 37.5 (12) | .0057 |
| No transplantation (incl. only chemotherapy), % (n) | 51.3 (59) | 62.1 (37) | 37.9 (22) | .1134 |
AML indicates acute myeloid leukemia; CR1, complete remission; CRT, calreticulin; DFS, disease-free survival; and OS, overall survival.